rHuEpo is pharmaceutical used to correct anemias associated with renal insufficiency, cancer and other diseases. Efforts to increase its efficacy in vivo by manipulating the protein’s structure resulted in novel Epo like agents. Epo mimetic agents and agents to increase endogenous production are underway. As Epo has tissue protective actions outside of erythropoiesis, designs try producing erythro-inactive molecules that still retain extra-hematopoietic activity. Data that Epo can trigger signaling in some cancer cells has raised attention of medical community and regulatory authorities.
COBISS.SI-ID: 24260313
rHuEPO se uspešno uporablja v medicini, deluje kot stimulator nastajanja rdečih krvnih celic. Tehnologija detekcije in ločevanja endogenega in eksogeno vnesenega EPO ni bila dostopna vse do leta 2000, ko so prvič uporabili metodo izoelektričnega fokusiranja za analizo zlorabe v športu. Problem detekcije rHuEPO je strukturna podobnost endogenemu EPO. Poleg tega je koncentracija EPO v človeških tekočinah zelo nizka. Metoda trenutno še ni v uporabi pri diagnostiki anemičnih bolnikov, vendar ima potencial za določanje vpliva rHuEPO in druge terapije na nivo izražanja in obliko endogenega EPO.
COBISS.SI-ID: 111111111